Effects of Vitamin D and Memantine on Repetitive Mild Traumatic Brain Injury via mTOR, TRPM2, and GABA Expression Levels on Juvenile Rats

Ismail GULSEN[1], Hakan AK[2], Mehmet Edip AKYOL[1], Ozlem OZMEN[3], Hamit Hakan ALP[4], Ozkan ARABACI[1]

[1]Van Yuzuncu Yil University, Faculty of Medicine, Department of Neurosurgery, Van, Türkiye
[2]Kirsehir Ahi Evran University Faculty of Medicine, Department of Neurosurgery, Kırşehir, Türkiye
[3]Mehmet Akif Ersoy University, Faculty Veterinary Medicine, Department of Pathology, Burdur, Türkiye
[4]Van Yuzuncu Yil University, Faculty of Medicine, Department of Biochemistry, Van, Türkiye

Corresponding author: Ismail GULSEN ✉ dr-ismailgulsen@hotmail.com

ABSTRACT

AIM: To investigate the effects of vitamin D and memantine on the healing process in juvenile rats with repetitive brain injury (rTBI) and to elucidate the mechanisms underlying these potential therapeutic effects.

MATERIAL and METHODS: Juvenile rats were randomly allocated into seven groups, with eight rats per group: sham-operated (Group I), trauma (Group II), memantine supplementation (10 mg/kg) pre-trauma (Group III), vitamin D supplementation (5 μg/kg) pre-trauma (Group IV), vitamin D supplementation post-trauma (Group V), memantine and vitamin D supplementation post-trauma (Group VI), and vitamin D supplementation pre- and post-trauma with post-trauma memantine supplementation (Group VII). A modified repeated weight drop model was employed to induce rTBI. Brain tissues and blood samples were collected for analysis. Expressions of the mammalian target of rapamycin (mTOR), temporary receptor potential (TRPM2), and GABA receptors were assessed via immunohistochemistry. Levels of 8-hydroxy-2-deoxyguanine (8-OHdG) were determined using high-performance liquid chromatography (HPLC). Matrix metalloproteinases -2 and -9, tissue inhibitors of metalloproteinases-1 and-2, and NADPH oxidation-4 levels were determined using commercially available enzyme-linked immunosorbent Test kits. Immunohistochemistry analyses were performed on the brain cortex and hippocampus.

RESULTS: The levels of 8OHdG/106dG, MMP-2, MMP-9, TIMP-1, -TIMP2, and NOX-4 were significantly higher in the trauma group than in the other groups. No difference was found between the control and Pre Vit D+Mem+Post Vit D groups regarding 8OHdG/106dG, MMP-2, -9 and NOX-4 levels. Normalized expressions of mTOR and TRPM2 were observed in Groups VI and VII. Conversely, GABA expression levels decreased in Group II, with the most pronounced therapeutic effects observed in Group VII.

CONCLUSION: Memantine and vitamin D positively affected rTBI when used alone. Their combined use exhibited greater therapeutic outcomes. These effects are mediated by mTOR mRNA, TRPM2 mRNA, and GABA mRNA expressions.

KEYWORDS: Repeated mild traumatic brain injury, Vit D, Memantine, mTOR signaling

INTRODUCTION

Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. In the United States, approximately 70 million individuals experience a TBI annually (11), with approximately 80% of these being mild TBI (mTBI) (28). While a single TBI can induce symptoms like increased stress and mental confusion (24), recurrent mTBI (rmTBI) often results in more severe short-term and

Ismail GULSEN   ⓘD : 0000-0002-2180-0360
Hakan AK   ⓘD : 0000-0001-6975-9822
Mehmet Edip AKYOL ⓘD : 0000-0002-5198-0219
Ozlem OZMEN   ⓘD : 0000-0002-1835-1082
Hamit Hakan ALP ⓘD : 0000-0002-9202-4944
Ozkan ARABACI ⓘD : 0000-0001-7546-8079

long-term physiological effects (40). Children are particularly vulnerable to rmTBI due to common incidents, such as falls, bicycle or motorcycle accidents, and sports-related injuries. Such repeated injuries during childhood can lead to persistent behavioral and neurological problems, including conditions such as seizures, sleep disturbances, neurodegenerative diseases, hormonal imbalances, and mental health issues (7).

Vitamin D (Vit D) is essential for cellular health and regular cellular functions (19). Numerous studies have explored the benefits of Vit D, either alone or combined with other compounds, in TBI, observing its influence on survival rates and disease outcomes (2,8). Despite the growing understanding of its mechanisms (23), research on Vit D's therapeutic potential for recurrent brain injuries, especially in children, remains limited.

MMT inhibits the activity of NMDA-5, providing neuroprotection by reducing glutamate-induced toxicity, which can be harmful to neurons, and aiding in cognitive recovery following TBI (20). Although memantine is used in various neurological disorders, its use in TBI, especially rmTBI, is not widespread. A limited number of studies have examined its role in recurrent brain injuries (26). To the best of our knowledge, only one study investigated memantine's role in recurrent brain injuries (32).

Matrix metalloproteinases (MMPs) are multifunctional enzymes that influence various cellular processes in the central nervous system (CNS) (16). MMPs manage the extracellular matrix components in both normal and pathological states of the CNS and peripheral nervous system (43). Elevated MMP activity is observed in various CNS conditions such as Alzheimer's disease, post-injury, or post-stroke brain damage (38,41). MMP-2 and MMP-9 are particularly important for growth, adaptability, and nervous system repair (43). Tissue Inhibitors of Metalloproteinases (TIMPs) are responsible for regulating MMPs by inhibiting MMP-1, MMP-2, and, MMP-9 (10).

Ion channels, composed of proteins, act as cellular gateways that facilitate ion exchange. The transient receptor potential (TRP) protein family is involved in various cellular functions. Usually, TRP channels are considered to be free cation channels and not just select cation channels (39). Among them, TRP-melastatin 2 (TRPM2) has been linked to oxidative stress-induced processes and inflammation. Its function is dependent on the presence of intracellular Ca^{2+}.

The mammalian target of rapamycin (mTOR) pathway is vital for various brain functions, including neuronal protection, cell growth, and learning how to change our minds (21). Neuronal mTOR supports protein synthesis necessary for cellular growth and repair, and mTOR-driven processes are crucial for recovery from CNS damage, including TBI-induced inflammation.

This study aimed to investigate the roles of memantine and Vit D in minimizing post-traumatic neural damage in juvenile rat brains following repeated trauma.

■ MATERIAL and METHODS

Animals

We obtained 56 male Wistar-albino rats, weighing between 70-85 g and aged three weeks, from the Experimental Medicine Application and Research Center. Ethical permission for the study was granted by the Animal Experiments Local Ethics Committee of Van Yuzuncu Yıl University, Turkey (2020/12-16, Date: 31.12.2020). The animals were randomly assigned to seven groups (eight per group). They were housed in an automatically controlled environment with a temperature of 22 ± 2 °C, 60% humidity, and a 12-hour light/dark cycle. Prior to the experiment, the animals were acclimatized to the environment to ensure that they were not stressed.

The rats had ad libitum access to food and water. A combination of Ketamine (80 mg) and xylazine (10 mg) body weight was administered intraperitoneally before sacrifice. All the procedures were performed in accordance with the principles of the Declaration of Helsinki. All staff members paid attention to minimizing animal suffering during each step of the experiment.

Experimental Protocol

The weight drop method was adapted from Feeney's falling weight (FFW) technique and modified according to the Mychasiuk method in the literature (15). The FFW was utilized for achieving an adequate cranium impact level, while the Mychasiuk method was implemented to reduce animal mortality and improve real-life conditions adaptation (32). The setup involved an aluminum foil-covered sponge placed in a basket. After anesthetization, animals were positioned on the aluminum foil (15,32). A brass cylinder weighing 150 grams was dropped from a height of 0.05 m onto the skull, guided by a vertical glass tube, over four days. The energy (E) of the impact was calculated using the following formula: E = mg x h.

In this formula, E represents energy, mg is mass times gravity, and h denotes height. This system allows for precise and repeatable injuries in different types of animals. This system enabled accurate and repeatable injuries in different types of animals. The animals were immediately placed in their cages following recovery after the weight drop.

Control – Sham-operated: Animals in this group continued their routine lives without any intervention

Trauma group: Following the Feeney model, animals underwent the weight-drop trauma daily for four days (15, 32). No medication or post-traumatic procedures were administered. The animals were sacrificed on the eighth day.

Memantine group with memantine supplementation after trauma: After the weight-drop trauma, the subjects received 10 mg/kg/day of memantine for four days, (44) and were sacrificed on the eighth day.

Pre-Vit D group -with Vit D supplementation before trauma: Animals received 5 μg/kg of Vit D, intraperitoneally, four days before the trauma, followed by the trauma procedure over the next four days. Sacrifice occurred on the eighth day.

Post Vit D group with Vit D supplementation after trauma: Similar to the previous groups, these animals received 5 µg/kg of Vit D, intraperitoneally, for four days post-trauma (42), and were sacrificed on the eighth day.

Post Vit D with memantine supplementation after trauma: Following the weight-drop trauma model, as in the previous groups, animals in this group were administered both memantine (10 mg/kg/day) and Vit D (5 µg/kg, intraperitoneally, for four days during a seven-day period. They were sacrificed on the eighth day.

Pre Vit D + Post Vit D and Memantine group with Vit D supplementation before and after trauma and memantine supplementation after trauma: Animals in this group received Vit D (5 µg/kg), intraperitoneally, starting four days before the weight-drop trauma and continuing until sacrifice. Additionally, they were administered memantine injections (10 mg/kg/day) for the four days following the trauma. Sacrifice occurred on the eighth day.

Histopathological Method

Brain samples were collected at the end of the necropsy. These samples were then fixed in a 10-percent neutral formalin solution for two days. Subsequently, the brain samples underwent standard histological processing. This process began with dehydration in progressively concentrated alcohol solutions. Subsequently, the tissues were treated with xylol using the Leica ASP300S automated tissue processor (Leica Microsystems, Wetzlar, Germany) and then covered with paraffin.

Tissue sections of 5 µm thickness were prepared using the Leica RM2155 rotary microtome (Leica Microsystems, Wetzlar, Germany). These sections were stained with Hematoxylin and Eosin and covered with glass slides, for observation under conventional light microscopy.

Immunohistochemical Method

Brain sections were immunostained using an active TRPM2 (TRPM2 antibody, ab11168), mTOR (mTOR antibody, ab32028; from Abcam, Cambridge, UK), and GABA-receptor antibodies (anti-GABA receptor alpha 5 antibodies, JB34-19, ET7107-08; from Hangzhou HuAn Biotechnology Co. Ltd., USA). In this study, we used Streptavidin and Biotin Peroxi-dase methods. The procedure began with incubation in the primary antibody for one hour, followed by a secondary im-munohistochemical analysis using a biotin-labeled secondary antibody and conjugate from the EXPOSE Mouse and Rabbit IHC Kit (AB80436). Diaminobenzidine was employed as the chromogen. For controls, the primary antibody was replaced with a antigenic dilution medium. All assessments were con-ducted on anonymized samples.

To quantify positive cells, we counted 100 cells across five random areas of the brain cortex and hippocampus (20 cells in each area). Using commercial analysis software we examined each section in detail. The processing included cropping of images, separation by colour channel, removal of artefacts, and use of an area tool to identify and count neighboring positive cells. Counts were performed blindly, and results were verified by a pathologist from another university The results were then analyzed using a database manual and a morphometric analysis and microphotography system (Olympus Co., Japan).

Biochemical Assays

To evaluate oxidative DNA damage, we assessed the levels of 8-OHdG using HPLC, following the methodology established by Kaur and Halliwell (25). The results are expressed as the ratio of 8-OHdG to 106 dG. This method comprises three stages. Initially, DNA extraction was performed using fresh blood samples, employing the PureLink Genomic DNA Mini Kit (Thermo Fisher Scientific, CA, USA).

Subsequently, the DNA samples were hydrolyzed using 60% v/v formic acid as detailed by Kaur and Halliwell (25). For the detection of 8-OHdG, an HPLC system equipped with an electrochemical and diode array detector (HPLC-ECD and HPLC-DAD; Waters 2465, The Netherlands) was utilized, as mentioned previously (37). Following hydrolysis, the DNA samples were mixed with HPLC solvent to a final volume of 1 mL. A 20 µL segment of this hydrolyzed mixture was then analyzed using HPLC-ECD and HPLC-DAD. The HPLC analysis employed a reverse phase column (RP-C18, 250 mm x 4.6 mm x 4.0 µm; Phenomenex, CA, USA). While the concentration of dG was monitored via absorbance at 245 nm, 8-OHdG was detected electrochemically at 600 mV. The concentration of 8-OHdG was quantified as the number of 8-OHdG molecules per 106 dG.

The levels of MMP-2, MMP-9, TIMP-1, TIMP-2, and NOX-4 were measured using specific ELISA kits according to the guidelines provided by the manufacturer (YLbiont YI Biotech Co. Ltd., Shanghai, China).

The total antioxidant capacity (TAS) and the total oxidant status (TOS) in the brain tissue were quantified using an automated colorimetric method as described by Erel O (13,14). The results were expressed in mmol Trolox/L for TAS and µmol 2HO Eq/L for TOS.

■ RESULTS

Immunohistochemistry Findings

Brain trauma caused marked histopathological lesions in the brain cortex, but not in the hippocampus. Immunohistochem-ical findings revealed increased mTOR and TRPM expression and decreased GABA expression in the cortex and hippocam-pus. Treatment with either memantine or Vit D resulted in ame-lioration. The combination of memantine and Vit D led to more effective amelioration, with the most marked improvement observed in Group VII.

Brain Cortex Histopathological Findings

Histopathological examination of the brain cortex showed normal tissue histology in the sham-operated group. In contrast, the trauma group exhibited marked hyperemia, hemorrhage, necrosis, and inflammatory cell infiltrations. A significant decrease in pathological findings was determined in Groups III, IV, V, VI, and VII, with a marked decrease observed in Group VII (Figure 1).

Figure 1: The microscopical appearance of the brain cortex between the groups. **A)** Normal tissue histology in the control group. **B)** Marked necrosis and inflammatory reaction (arrow) in the trauma group. **C)** Decreased pathological reaction (arrow) in the memantine group. **D)** Decreased pathological findings (arrow) in Pre trauma treatment with Vit D. **E)** Moderate decrease in pathological findings (arrow) in Post-trauma treatment with Vit D. **F)** Moderate decrease in pathological findings in (arrow) Memantine + post-Vit D treatment group, **G)** Marked amelioration in pathological findings (arrow) in Pre trauma Vit D + post trauma Vit D and Memantine groups. HE, scale bars=50µm.

Figure 2: Histopathological appearance of the hippocampus between the groups. Normal tissue histology in the control group **(A)**; in the trauma group **(B)**; in the memantine group **(C)**; in Pre trauma treatment with Vit D group **(D)**; in the Post-trauma treatment with Vit D group **(E)**; in Memantine + post-trauma treatment Vit D group **(F)**; in Pre trauma Vit D + post trauma Vit D and Memantine groups **(G)**. HE, scale bars=50µm.

Hippocampus Histopathological Findings

No pathological findings were observed in any group during the hippocampal histopathological examination (Figure 2).

mTOR Immunohistochemistry Findings in Brain Cortex

mTOR immunohistochemistry findings indicated increased expressions in the trauma group. Decreased expressions were observed in other groups. In Group IV, mTOR expression levels (46.12 ± 2.69) were similar to those in Group III (47.87 ± 2.79). However, Group V exhibited a better therapeutic effect (37.00 ± 1.92). Group VI also showed significantly decreased mTOR expression levels (33.87 ± 3.31). The most marked amelioration was observed in Group VII (20.87 ± 1.12) (Table I, Figure 3).

mTOR Histopathological Findings in the Hippocampus

In the hippocampus, Group II showed significantly increased

mTOR expressions. Slightly decreased expression levels were noted in neurons Groups III (21.12 ± 1.72), IV (15.75 ± 1.03), and V (16.55 ± 1.19). A moderate decrease was observed in Group VI (11.87 ± 1.12), while Group VII exhibited the best therapeutic effect (9.00 ± 0.75), with significant reduction in mTOR staining in neurons (Table I, Figure 4).

TRPM2 Immunohistochemistry Findings in Brain Cortex

TRPM2 immunohistochemistry findings revealed increased expressions in Group II. Decreased expressions were noted in Group III (45.75 ± 1.66). Groups IV and V had TRPM2 expression levels of 41.50 ± 1.41 and 37.62 ± 2.19, respectively. A significant decrease was observed in Group VI (33.75 ± 1.75), with the most effective outcomes in Group VII (27.50 ± 1.85).

TRPM2 is an oxidative stress-sensitive channel, and our results demonstrate that memantine and Vit D play crucial roles in intracellular cascade regulation (Table I, Figure 5).

TRPM2 Immunohistochemistry Findings in the Hippocampus

Similar to the brain cortex, the hippocampal TRPM2 expression levels in the trauma group (Group II) showed a statistically significant increase (51.37 ± 3.33). Memantine treatment (Group III) reduced TRPM2 expression levels (46.50 ± 2.07). Vit D-administered groups (Groups IV and V) showed more reduction in TRPM2 expression levels (44.50 ± 1.51 and 41.62 ± 1.30, respectively) than the memantine-treated group (Group III). However, the reductions in Groups VI and VII were much greater than those in the other groups. The best

**Table I:** Statistical Analysis Results of Immunohistochemical Scores Between Groups

		Control	Trauma	Memantine	Pre Vit D	Post Vit D	Mem + post Vit D	Pre Vit D + + post Vit D -Mem
mTOR	B	22.75 ± 2.21[a]	56.37 ± 3.02[b]	47.87 ± 2.79[c]	46.12 ± 2.69[c]	37.00 ± 1.92[d]	33.87 ± 3.31[e]	20.87 ± 1.12[a]
	H	10.00 ± 1.63[ae]	24.87 ± 3.72[b]	21.12 ± 1.72[c]	15.75 ± 1.03[d]	16.55 ± 1.19[d]	11.87 ± 1.12[e]	9.00 ± 0.75[a]
TRPM2	B	28.00 ± 0.81[a]	48.87 ± 1.95[b]	45.75 ± 1.66[c]	41.50 ± 1.41[d]	37.62 ± 2.19[e]	33.75 ± 1.75[f]	27.50 ± 1.85[a]
	H	29.00 ± 3.16[a]	51.37 ± 3.33[b]	46.50 ± 2.07[c]	44.50 ± 1.51[c]	41.62 ± 1.30[d]	26.50 ± 2.13[e]	18.25 ± 1.48[f]
GABA Recept.	B	55.75 ± 0.95[a]	23.37 ± 1.68[b]	39.25 ± 4.80[c]	46.00 ± 1.85[d]	47.87 ± 1.88[de]	49.87 ± 1.24[e]	56.75 ± 2.49[a]
	H	56.25 ± 0.95[a]	28.50 ± 1.19[b]	34.50 ± 1.19[c]	34.25 ± 1.38[c]	35.62 ± 1.59[c]	44.00 ± 2.00[d]	55.37 ± 4.10[a]

: Data expressed mean ± standard deviation (SD). One-way ANOVA Duncan test. **: The differences between the groups carrying different letters in same colon are statistically significant, p<0.001. **B: Brain, **H:** Hippocampus.*


Figure 3: mTOR immunohistochemistry findings in brain cortex between the groups. **A)** Control group animals **B)** Marked increase in expression (arrows) in neurons in the trauma group. **C)** Slightly decreased expressions in neurons in the memantine group. **D)** Slightly decreased expressions in neurons in the Pre trauma treatment with Vit D group. **E)** Slightly decreased expression in neurons in the Post-treatment Vit D group. **F)** Moderate decrease in neurons in the Memantine + post-trauma treatment with Vit D group. **G)** A marked increase in neurons in the Pre trauma Vit D + post-trauma Vit D and Memantine groups. Streptavidin biotin peroxidase method, scale bars=50μm.

Figure 4: mTOR immunohistochemistry findings in the hippocampus among the groups. **A)** Slight expression in the control group. **B)** A marked increase in neurons (arrows) in the trauma group. **C)** Slightly decreased expression in neurons in the memantine group. **D)** Slightly decreased neuron expression in the Pre trauma treatment with the Vit D group. **E)** Slightly decreased neuron expression in the Post-trauma treatment with the Vit D group. **F)** Moderate decrease in expression in neurons in the Memantine + post-trauma treatment with Vit D group. **G)** A marked increase in neurons in the Pre trauma Vit D + post-trauma Vit D and Memantine groups. Streptavidin biotin peroxidase method, scale bars=50µm.

Figure 5: TRPM immunohistochemistry findings in the brain cortex between the groups. **A)** Slight expression in the control group. **B)** A marked increase in neurons (arrows) in the trauma group. **C)** Slightly decreased expression in neurons in the memantine group. **D)** Slightly decreased neuron expression in the Pre trauma treatment with the Vit D group. **E)** Slightly decreased neuron expression in the Post-trauma treatment with the Vit D group. **F)** Moderate decrease in expression in neurons in the Memantine + post-trauma treatment with Vit D group. **G)** A marked increase in neurons in the Pre trauma treatment Pre trauma Vit D + post-trauma Vit D and Memantine groups. Streptavidin biotin peroxidase method, scale bars=50µm.

therapeutic effect was observed in Group VII (18.25 ± 1.48). (Table I, Figure 6).

**GABA Receptor Immunohistochemistry Findings in Brain Cortex**

GABA receptor immunohistochemistry in the brain cortex showed decreased expression levels in the trauma group (Group II, 23.37 ± 1.68). Following memantine administration (Group III), the expression levels increased (39.20 ± 4.80). Groups IV and V exhibited higher GABA expression levels (46.00 ± 1.85 and 47.87 ± 1.88, respectively). Group VI demonstrated better effects (49.87 ± 1.24), but the most pronounced therapeutic effects were observed in Group VII (56.75 ± 2.49) (Table I, Figure 7).

Figure 6: TRPM immunohistochemistry findings in the hippocampus between the groups. **A)** Slight expression in the control group. **B)** A marked increase in neurons (arrows) in the trauma group. **C)** Slightly decreased expression in neurons in the memantine group. **D)** Slightly decreased neuron expression in the Pre trauma treatment with the Vit D group. **E)** Slightly decreased neuron expression in the Post-trauma treatment with the Vit D group. **F)** Moderate decrease in expression in neurons in the Memantine + post-trauma Vit D group. **G)** A marked increase in neurons in the Pre Vit D + Post trauma Mem + Vit D groups. Streptavidin biotin peroxidase method, scale bars=50μm.

Figure 7: GABA receptor immunohistochemistry findings in the brain cortex between the groups. **A)** Marked expression in neurons in the control group. **B)** A marked decrease in expression in neurons (arrows) in the trauma group. **C)** Slight increase in expression in neurons in the memantine group. **D)** A moderate increase in neuron expression in the Pre trauma treatment with the Vit D group. **E)** A moderate increase in expression in neurons in the Post-trauma treatment with the Vit D group. **F)** A moderate increase in expression in neurons in the Memantine + post-trauma treatment with the Vit D group. **G)** A marked increase in expression in neurons in the Pre Vit D + Post trauma Mem + Vit D groups. Streptavidin biotin peroxidase method, scale bars=50μm.

GABA Receptor Immunohistochemistry Findings in the Hippocampus

In the hippocampus, GABA receptor immunohistochemistry revealed decreased expression levels in the trauma group (Group II, 28.50 ± 1.19). Memantine administration (Group III) led to increased expression levels (34.50 ± 1.19). Group IV and Group V also showed increased GABA expression levels (34.25 ± 1.38 and 35.62 ± 1.59, respectively). Group VI showed improved effects (44.00 ± 2.00). However, Group VII exhibited the most substantial therapeutic effects (55.37 ± 4.10) (Table I, Figure 8).

Biochemical Findings

Examination of the 8-OHdG/106dG ratios revealed that the trauma group had the highest values, notably differing from

Figure 8: GABA receptor immunohistochemistry findings in the hippocampus among the groups. **A)** Marked expression in the control group. **B)** A marked decrease in neurons (arrows) in the trauma group. **C)** Slight increase in neurons in the memantine group. **D)** Moderately increased neuron expression in the Pre trauma treatment with Vit D group. **E)** A moderate increase in neurons in the Post-trauma treatment with the Vit D group. **F)** A moderate increase in neurons in the Memantine + post-trauma treatment with the Vit D group. **G)** A marked increase in neurons in the Pre Vit D + Post trauma Mem + Vit D groups. Streptavidin biotin peroxidase method, scale bars=50μm.

Table II: The Levels of All Variables in Groups

	Control	Trauma	Memantine	Pre Vit D	Post Vit D	Post Mem + Vit D	Pre Vit D + +Post Vit D+ Mem
8-OHdG / 10⁶dG	0.81 ± 0.14^a	3.12 ± 0.25^b	1.85 ± 0.33^c	$1.53 \pm 0.31^{c,d}$	1.26 ± 0.21^d	1.25 ± 0.38^d	0.82 ± 0.07^a
NOX-4 (μmol/L)	8.12 ± 0.83^a	18.5 ± 6.56^c	14.8 ± 3.25^b	13.5 ± 2.21^b	14.9 ± 2.31^b	8.96 ± 1.46^a	9.82 ± 1.07^a
MMP-2 (ng/mL)	30.8 ± 3.65^a	46.3 ± 4.94^c	35.8 ± 3.97^a	44.1 ± 6.09^c	$43.1 \pm 5.07^{b,c}$	$36.6 \pm 3.83^{a,b}$	31.6 ± 1.92^a
MMP-9 (ng/mL)	0.42 ± 0.07^a	0.87 ± 0.11^c	0.98 ± 0.09^b	0.74 ± 0.09^b	0.75 ± 0.06^b	0.73 ± 0.11^b	0.47 ± 0.07^a
TIMP-1 (ng/mL)	1.68 ± 0.19^a	0.56 ± 0.11^d	$1.05 \pm 0.27^{b,c}$	$1.26 \pm 0.26^{b,c}$	0.93 ± 0.07^c	1.31 ± 0.32^b	$1.11 \pm 0.06^{b,c}$
TIMP-2 (ng/mL)	8.02 ± 0.97^a	3.21 ± 0.17^d	4.47 ± 0.44^c	$3.91 \pm 0.77^{c,d}$	$4.22 \pm 0.24^{c,d}$	$3.98 \pm 0.28^{c,d}$	6.55 ± 0.95^b

Different letters in the same row show significant differences. P<0.05. The results were expressed as mean±standart deviation.
[a]p<0.001 vs Control group, [b]p<0.001 vs Trauma group, [c]p<0.001 vs Post trauma Memantin group, [d]p<0.001 vs Pre trauma Vit D group, [e]p< 0.001 vs Post trauma Vit D group, [f]p<0.001 vs Pre trauma Vit D +Post trauma Mem + Vit D group.

other groups. The Pre Vit D+Mem+Post Vit D group displayed lower levels, not significantly differing from the control group. Less memantine was used in the trauma group than in any other group, but more memantine was used in all groups except the Pre Vit D group. The Pre Vit D, Post Vit D, and Mem+Post Vit D groups showed no notable differences in 8-OHdG/106dG levels (Table II, Figure 9).

The NOX-4 levels in the trauma group notably surpassed those in the other groups, with the control group having the lowest readings. Although the control group's levels were similar to those of both the Mem+Post Vit D and Pre Vit D+Mem+Post Vit D groups, the memantine group's levels were lower than those of the trauma group. The memantine, Pre-Vit D, and Post-Vit D groups had similar NOX-4 levels, but they were discernibly lower than those in the trauma group and higher

than those in the control group, Mem+ Post-Vit D, and Pre-Vit D + Mem + Post-Vit D groups (Table II, Figure 10).

The MMP-2 levels in the Pre Vit D+Mem+Post Vit D group were noticeably lower than those in the other groups, with no significant difference from the control group. The levels in the Mem+Post Vit D group were lower than those in the Pre Vit D and Trauma groups but remained similar to the control, memantine, and Pre Vit D+Mem+Post Vit D groups (Table II, Figure 11).

Regarding MMP-9, the Pre Vit D+Mem+Post Vit D group's readings were distinctly lower than most, except for the control group. The Trauma group showed the highest MMP-9 levels, surpassing all other groups. The memantine, Pre Vit D, Post Vit D, and Mem+Post Vit D groups exhibited similar MMP-9 values (Table II, Figure 12).

Figure 9: Distribution of 8-OHdG/10^6 dG levels between groups. Box plot presentation.

Figure 10: Distribution of NOX-4 (μmol/L) levels between groups. Box plot presentation.

Figure 11: Distribution of MMP-2 ng/mL) levels between groups. Box plot presentation.

TIMP-1 levels were highest in the control group, contrasting with all other groups. The Trauma group had the lowest TIMP-1 levels, while among the treatment groups, those in the Post Vit D group were the lowest. The Mem+Post Vit D group had the highest TIMP-1 level among treatments, yet it was not significantly different from the Memantine, Pre Vit D, and Pre Vit D+Mem+Post Vit D groups (Table II, Figure 13).

The peak TIMP-2 levels were observed in the control group, which contrasted notably with other groups. The Trauma group had the lowest TIMP-2 levels, but among treatments, the Pre Vit D+Mem+Post Vit D group was the highest, differing notably from all groups except the control (Table II, Figure 14).

Correlation analysis revealed a clear positive association between 8-OHdG/106 dG and NOX-4 levels. Additionally, 8-OHdG/106dG levels positively correlated with both MMP-2 and MMP-9 levels. NOX-4 was negatively correlated with TIMP-1 and TIMP-2 but positively correlated with MMP-2

and MMP-9. Clear positive and negative correlations were found between TIMP-1 and TIMP-2 and MMP-2 and MMP-9, respectively. All the correlations are presented in Table III and Figure 14.

■ DISCUSSION

The results of this study indicate that the use of Vit D and/or memantine, either separately or in combination, promotes healing in repetitive brain injury in juvenile rats. Notably, combined usage provided more substantial healing effects through modulation of mTOR, TRPM2, and GABA expression levels.

The use of Vit D in patients with head trauma has been extensively studied. According to a recent randomized, placebo-controlled study, Vit D administration at different doses had different effects on serum inflammatory factor

Figure 12: Distribution of MMP-9 ng/mL) levels between groups. Box plot presentation.

**Figure 13:** Distribution of TIMP-1 ng/mL) levels between groups. Box plot presentation.

Figure 14: Distribution of TIMP-2 ng/mL) levels between groups. Box plot presentation.

Table III: The Correlation Analysis of Variables

Correlations		8-OHdG/10⁶dG	NOX-4 (μmol/L)	TIMP-1 (ng/mL)	TIMP-2 (ng/mL)	MMP-9 (ng/mL)	MMP-2 (ng/mL)
8-OHdG/10⁶dG	r	1					
	p						
	N	50					
NOX-4 (μmol/L)	r	0.626**	1				
	p	**0.000**					
	N	50	50				
TIMP-1 (ng/mL)	r	-0.661**	-0.612**	1			
	p	**0.000**	**0.000**				
	N	50	50	50			
TIMP-2 (ng/mL)	r	-0.613**	-0.555**	0.564**	1		
	p	**0.000**	**0.000**	**0.000**			
	N	50	50	50	50		
MMP-9 (ng/mL)	r	0.597**	0.526**	-0.527**	-0.789**	1	
	p	**0.000**	**0.000**	**0.000**	**0.000**		
	N	50	50	50	50	50	
MMP-2 (ng/mL)	r	0.530**	0.579**	-0.456**	-.690**	.667**	1
	p	**0.000**	**0.000**	**0.001**	**.000**	**.000**	
	N	50	50	50	50	50	50

*****. Correlation is significant at the 0.01 level (2-tailed). **r**= Correlation coefficient.*

Figure 15: The correlation matrix between variables.

levels and mortality in patients with severe TBI. Based on the findings of this study, Vit D may help patients with TBI achieve better clinical outcomes by lowering the rates of infection, inflammation-related morbidity, and death.

The age group in that study ranged from 18 to 65 years, encompassing young adults, adults, and older patients (19). A separate review focused on the relationship between Vit D and neonatal hypoxic-ischemic brain injury. This review demonstrated that Vit D administration is beneficial in mitigating brain damage (41). Vit D has been identified as a protector against traumatic brain injury through the modulation of microglial polarization and neuroinflammation, dependent on the TLR4/MyD88/NF-κB pathway (23). Another study

investigated the synergistic effects of Vit D and progesterone on brain injury, particularly in elderly patients with head trauma, and reported significant results (8).

Our study differs from the existing literature in several ways.

The first distinction lies in the age range of our study group, which aligns with the infancy and play-age childhood group. Children are particularly vulnerable to trauma, and, to our knowledge, no study specifically addresses this age group. The second distinction involves the severity of trauma. Recurrent mild head trauma during infancy and play-age childhood, occurs for various reasons, often due to falling, getting up, or bumping one's head, is common. Our study emphasizes the

importance of addressing these types of injuries. However, the mechanism of action observed in our study aligns with that reported in the literature. Consistent with previous findings, we found that the combined use of Vit D led to more effective healing outcomes.

Memantine is widely used in the clinical treatment of many neurological diseases. There have been various studies have been various studies investigating memantine's mechanism of action, and it has been investigated in several TBI models (6,12,26,36). A study conducted in 2018, explored memantine's effect on repetitive mild brain damage using adult rats. This study demonstrated the effectiveness of memantine in this context (31). Similarly, our study focused on repetitive mild brain injury but differed in the age range of the subjects. Additionally, we revealed another difference by examining the combined effects of Vit D.

Memantine is known to protect brain tissue from apoptosis and excitotoxicity through NMDA-type glutamate receptors following TBI (26). Moreover, supplementing certain vitamins might enhance the efficacy of drugs.

Accordingly, we investigated whether Vit D supplementation amplifies the effects of memantine. Our findings indicated that Vit D has supportive and protective effects against the rmTBI model. Administration of Vit D before and after trauma significantly reduced mTOR, TRPM2 expression, MMP-2 and MMP-9 levels, as well as DNA damage in the hippocampal and cerebral cortex of young rats with rmTBI. However, decreased GABA receptor levels in the trauma group were altered in Groups II, IV, V, and VI, with the most protective effect observed in Group VII.

Studies have highlighted various intracellular signaling cascades in the pathogenesis of rmTBI. Increasing evidence suggests that mTOR signaling is an important control mechanism of synaptic plasticity.

Recent studies have suggested that the neurodevelopmental processes associated with neuropsychiatric disorders involve the mTOR signaling cascade (18). Phosphorylation of mTOR and its downstream targets increased within 30 minutes post-TBI in adult rats (3). Our study observed a significant induction of mTOR expression in the trauma group, whereas combined memantine and Vit D administration markedly reduced mTOR expression levels in brain tissue and hippocampal regions. The immunomodulatory and antiproliferative properties of Vit D, particularly its hormonal form, 1,25-dihydroxy Vit D (1,25(OH)2D). These effects highlight the potential use of Vit D in the treatment of various disorders. By promoting DNA damage-inducible transcript 4 (DDIT4) and regulating the development and DNA damage response 1 (REDD1), two key components of the mTOR signaling cascade, 1,25(OH)2D can modulate the activity of these molecules (29). Our results align with these findings, with decreased mTOR expression observed in the brain cortex and hippocampus of Group VII. Alongside mTOR signaling outcomes, we also assessed DNA damage levels in Group VII. Another study highlighted the hippocampal neuroprotection induced by early inhibition of mTORC1 with a single dose of rapamycin in a TBI model (34).

Following TBI, there is an observed increase in reactive oxygen species (ROS), apoptotic cell death, and lipid peroxidation (17). These molecules are responsible for the secondary tissue damage. Vit D is a known antioxidant that protects cells against ROS (5). Our results also confirmed that Vit D alone significantly reduced TOS levels in the brain.

In response to rmTBI, several physiopathological cascades occur, including excitotoxicity and oxidative stress. we investigated the impact of Vit D on the expression levels of the TRPM2 channel, a cation-permeable ion channel activated by oxidative stress, in both the hippocampal and cerebral cortex regions. Consistent with previous studies (9), we found significantly increased TRPM2 expression levels in these areas. However, memantine and Vit D supplementation notably decreased these levels. Particularly, Vit D supplementation, both pre- and post-trauma, regulated TRPM2 expression levels in control group animals compared to injury model rats. Inflammation, cell death mediated by inflammation, and oxidative stress have all been shown to activate TRPM2 channels. Inflammation has a key role in rmTBI because it promotes neurotoxicity. We found similar histopathological findings in in the brain cortex of the animals in the trauma group. TRPM2 channels regulate intracellular calcium (Ca2+) levels, which increase in response to oxidative stress, subsequently heightening the susceptibility to apoptotic cell death. TRPM2 channels participate in neuroinflammation following tissue damage, as in (27).

MMPs are a broad family of zinc-dependent endopeptidases secreted by various cell types, including astrocytes, endothelial cells, and neurons. They are primarily responsible for apoptosis and remodeling of the extracellular matrix (1). Their levels typically rise during pathophysiological conditions to break down elements of the extracellular matrix and interfere with the blood-brain barrier. MMPs dysregulate apoptotic cascades following tissue damage by triggering specific receptors and mediators. Additionally, hormones, cytokines, and growth factors can regulate MMP activation, which may vary during development and adolescence.

Oxidative agents, known as ROS, readily target guanine bases in DNA, leading to the formation of 8-hydroxydeoxyguanosine (8-OHdG). This compound tends to pair with thymidine instead of cytosine. Therefore, 8-OHdG is commonly viewed as an indicator of mutations resulting from oxidative damage.

Increased ROS levels can cause DNA damage and strand fracture. ROS readily attack DNA's guanine bases to produce 8-OHdG. Generally, 8-OHdG is considered as a biomarker of oxidative stress-related mutagenesis (33-35). We measure 8-OHdG levels from nucleic acids extracted from the brain tissue relative to dG to assess DNA damage (4). Elevated 8-OHdG levels have been observed in patients with neurodegenerative diseases (30). In our study, 8-OHdG/106 dG levels were significantly higher in the trauma group. However, administering Vit D both before and after trauma, particularly in combination with memantine, significantly reduced 8-OHdG/106 dG levels. These findings suggest a protective role for Vit D against mutations.

Enzymes repair damaged DNA without 8-OHdG, although postmitotic neurons have limited DNA repair capacity and may be particularly vulnerable to modified nucleotide damage. Dysfunctional DNA repair can trigger apoptosis in neurons (22). Our study showed that rmTBI could increase 8-OHdG accumulation due to oxidative damage and further disrupt the DNA damage mechanism.

These findings indicate that brain trauma caused marked histopathological lesions in the cortex, but not in the hippocampus or cerebellum. Immunohistochemical findings showed increased expressions of mTOR and TRPM while GABA expressions decreased in the brain cortex, hippocampus, and cerebellum. Memantine and Vit D treatments resulted in amelioration, with the most effective improvement observed in the Pre Vit D + Post trauma Mem + Vit D group.

CONCLUSION

Vit D administration plays a crucial role in juvenile rats. Supplementation with Vit D before and after trauma enhances the effectiveness of memantine by regulating intracellular signaling cascades and reducing oxidant molecule levels. Administering Vit D can thereby reduce DNA damage levels. Practical and easy use of Vit D and memantine supplementation may offer better outcomes against the rmTBI model in juveniles.

Declarations

AUTHORSHIP CONTRIBUTION

Study conception and design: IG

Data collection: MEA, OA

Analysis and interpretation of results: OO, HHA

Draft manuscript preparation: HA, IG

Critical revision of the article: IG, HHA

All authors (IG, HA, MEA, OO, HHA, OA) reviewed the results and approved the final version of the manuscript.

REFERENCES

1. Abdul-Muneer PM, Pfister BJ, Haorah J, Chandra N: Role of matrix metalloproteinases in the pathogenesis of traumatic brain injury. Mol Neurobiol 53:6106-6123, 2016. https://doi.org/10.1007/s12035-015-9520-8

2. Arabi SM, Sedaghat A, Ehsaei MR, Safarian M, Ranjbar G, Rezaee H, Rezvani R, Tabesh H, Norouzy A: Efficacy of high-dose versus low-dose vitamin D supplementation on serum levels of inflammatory factors and mortality rate in severe traumatic brain injury patients: Study protocol for a randomized placebo-controlled trial. Trials 21:685, 2020. https://doi.org/10.1186/s13063-020-04622-6

3. Arachchige Don AS, Tsang CK, Kazdoba TM, D'Arcangelo G, Young W, Steven Zheng XF: Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries. Drug Discov Today 17:861-868, 2012. https://doi.org/10.1016/j.drudis.2012.04.010

4. Atalay T, Gulsen I, Colcimen N, Alp HH, Sosuncu E, Alaca I, Ak H, Ragbetli MC: Resveratrol treatment prevents hippocampal neurodegeneration in a rodent model of traumatic brain injury. Turk Neurosurg 27:924-930, 2017. https://doi.org/10.5137/1019-5149.JTN.17249-16.2

5. Berridge MJ: Vitamin D, reactive oxygen species, and calcium signaling in aging and disease. Philos Trans R Soc Lond B Biol Sci 371: 20150434, 2016. https://doi.org/10.1098/rstb.2015.0434

6. Biegon A, Fry PA, Paden CM, Alexandrovich A, Tsenter J, Shohami E: Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits. Proc Natl Acad Sci USA 101:5117-5122, 2004. https://doi.org/10.1073/pnas.0305741101

7. Bramlett HM, Dietrich WD: Long-term consequences of traumatic brain injury: Current status of potential mechanisms of injury and neurological outcomes. J Neurotrauma 32:1834-1848, 2015. https://doi.org/10.1089/neu.2014.3352

8. Cekic M, Stein DG: Traumatic brain injury and aging: is a combination of progesterone and vitamin D hormone a simple solution to a complex problem? Neurotherapeutics 7:81-90, 2010. https://doi.org/10.1016/j.nurt.2009.10.017

9. Cook NL, Vink R, Helps SC, Manavis J, Van Den Heuvel C: Transient receptor potential melastatin 2 expression increases after experimental traumatic brain injury in rats. J Mol Neurosci 42:192-199, 2010. https://doi.org/10.1007/s12031-010-9347-8

10. Crocker SJ, Pagenstecher A, Campbell IL: The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 75:1-11, 2004. https://doi.org/10.1002/jnr.10836

11. Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, Agrawal A, Adeleye AO, Shrime MG, Rubiano AM, Rosenfeld JV, Park KB: Estimating the global incidence of traumatic brain injury. J Neurosurg 130:1080-1097, 2019. https://doi.org/10.3171/2017.10.JNS17352

12. Effgen GB, Morrison B: Memantine reduced cell death, astrogliosis, and functional deficits in an in vitro model of repetitive mild traumatic brain injury. J Neurotrauma 34:934-942, 2017. https://doi.org/10.1089/neu.2016.4528

13. Erel O: A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103-1111, 2005. https://doi.org/10.1016/j.clinbiochem.2005.08.008

14. Erel O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277-285, 2004. https://doi.org/10.1016/j.clinbiochem.2003.11.015

15. Feeney DM, Boyeson MG, Linn RT, Murray HM, Dail WG: Responses to cortical injury: I. Methodology and local effects of contusions in the rat. Brain Res 211:67-77,1981. https://doi.org/10.1016/0006-8993(81)90067-6

16. Guilfoyle MR, Carpenter KLH, Helmy A, Pickard JD, Menon DK, Hutchinson PJA: Matrix metalloproteinase expression in contusional traumatic brain injury: A paired microdialysis study. J Neurotrauma 32:1553-1559, 2015. https://doi.org/10.1089/neu.2014.3764

17. Gulsen I, Ak H, Colcimen N, Alp HH, Akyol ME, Demir I, Atalay T, Balahroglu R, Ragbetli M: Neuroprotective effects of thymoquinone on the hippocampus in a rat model of traumatic brain injury. World Neurosurg 86:243-249, 2016. https://doi.org/10.1016/j.wneu.2015.09.052

18. Gururajan A, Van Den Buuse M: Is the mTOR-signalling cascade disrupted in Schizophrenia? J Neurochem 129: 377-338, 2014. https://doi.org/10.1111/jnc.12622

19. Harms LR, Burne THJ, Eyles DW, McGrath JJ: Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab 25:657-669, 2011. https://doi.org/10.1016/j.beem.2011.05.009

20. He S, Bausch SB: Synaptic plasticity in glutamatergic and GABAergic neurotransmission following chronic memantine treatment in an in vitro model of limbic epileptogenesis. Neuropharmacol 77:379-386, 2014. https://doi.org/10.1016/j.neuropharm.2013.10.016

21. Jaworski J, Sheng M: The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol 34:205-219, 2006. https://doi.org/10.1385/MN:34:3:205

22. Jeppesen DK, Bohr VA, Stevnsner T: DNA repair deficiency in neurodegeneration. Prog Neurobiol 94:166-200, 2011. https://doi.org/10.1016/j.pneurobio.2011.04.013

23. Jiang H, Yang X, Wang Y, Zhou C: Vitamin D protects against traumatic brain injury via modulating TLR4/MyD88/NF-κB pathway-mediated microglial polarization and neuroinflammation. Biomed Res Int 2022:3363036, 2022. https://doi.org/10.1155/2022/3363036

24. Kamnaksh A, Ahmed F, Kovesdi E, Barry ES, Grunberg NE, Long JB, Agoston DV: Molecular mechanisms of increased cerebral vulnerability after repeated mild blast-induced traumatic brain injury. Translational Proteomics 3:22-37, 2014. https://doi.org/10.1016/j.trprot.2013.11.001

25. Kaur H, Halliwell B: Measurement of oxidized and methylated DNA bases by HPLC with electrochemical detection. Biochem J 318:21-23, 1996. https://doi.org/10.1042/bj3180021

26. Khan S, Ali A, Kadir B, Ahmed Z, Di Pietro V: Effects of memantine in patients with traumatic brain injury: A systematic review. Trauma Care 1:1-14, 2021. https://doi.org/10.3390/traumas1010001

27. Kühn FJP, Heiner I, Lückhoff A: TRPM2: A calcium influx pathway regulated by oxidative stress and the novel second messenger ADP-ribose. Pflugers Arch 451:212-219, 2005. https://doi.org/10.1007/s00424-005-1446-y

28. Laker SR: Epidemiology of concussion and mild traumatic brain injury. PM R 3:S354-358, 2011. https://doi.org/10.1016/j.pmrj.2011.07.017

29. Lisse TS, Hewison M: Vitamin D: A new player in the world of mTOR signaling. Cell Cycle 10:1888-1889, 2011. https://doi.org/10.4161/cc.10.12.15620

30. Liu Z, Cai Y, He J: High serum levels of 8-OHDG are an independent predictor of post-stroke depression in Chinese stroke survivors. Neuropsychiatr Dis Treat 14:587-596, 2018. https://doi.org/10.2147/NDT.S155144

31. Mei Z, Qiu J, Alcon S, Hashim J, Rotenberg A, Sun Y, Meehan, WP, Mannix R: Memantine improves outcomes after repetitive traumatic brain injury. Behav Brain Res 340:195-204, 2018. https://doi.org/10.1016/j.bbr.2017.04.017

32. Mychasiuk R, Farran A, Angoa-Perez M, Briggs D, Kuhn D, Esser MJ: A novel model of mild traumatic brain injury for juvenile rats. J Vis Exp 94:51820, 2014. https://doi.org/10.3791/51820

33. Nakamura T, Keep RF, Hua Y, Hoff JT, Xi G: Oxidative DNA injury after experimental intracerebral hemorrhage. Brain Res 1039:30-36, 2005. https://doi.org/10.1016/j.brainres.2005.01.036

34. Nikolaeva I, Crowell B, Valenziano J, Meaney D, D'Arcangelo G: Beneficial effects of early mTORC1 inhibition after traumatic brain injury. J Neurotrauma 33:183-193, 2016. https://doi.org/10.1089/neu.2015.3899

35. Ock CY, Kim EH, Choi DJ, Lee HJ, Hahm KB, Chung MH: 8-Hydroxydeoxyguanosine: Not mere biomarker for oxidative stress, but remedy for oxidative stress-implicated gastrointestinal diseases. World J Gastroenterol 18:302-308, 2012. https://doi.org/10.3748/wjg.v18.i4.302

36. Rao VLR, Dogan A, Todd KG, Bowen KK, Dempsey RJ: Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 911:96-100, 2001. https://doi.org/10.1016/S0006-8993(01)02617-8

37. Shigenaga MK, Aboujaoude EN, Chen Q, Ames BN: Assays of oxidative DNA damage biomarkers 8-oxo-2'-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 234:16-33, 1994. https://doi.org/10.1016/0076-6879(94)34073-0

38. Sifringer M, Stefovska V, Zentner I, Hansen B, Stepulak A, Knaute C, Marzahn J, Ikonomidou C: The role of matrix metalloproteinases in infant traumatic brain injury. Neurobiol Dis 25:526-535, 2007. https://doi.org/10.1016/j.nbd.2006.10.019

39. Sita G, Hrelia P, Graziosi, Ravegnini G, Morroni F: TRPM2 in the brain: Role in health and disease. Cells 7:82, 2018. https://doi.org/10.3390/cells7070082

40. Stern RA, Riley DO, Daneshvar DH, Nowinski CJ, Cantu RC, McKee AC: Long-term consequences of repetitive brain trauma: Chronic traumatic encephalopathy. PM R 3:S460-467, 2011. https://doi.org/10.1016/j.pmrj.2011.08.008

41. Stessman LE, Peeples ES: Vitamin D and its role in neonatal hypoxic-ischemic brain injury. Neonatology 113:305-312, 2018. https://doi.org/10.1159/000486819

42. Tang H, Hua F, Wang J, Sayeed I, Wang X, Chen Z, Yousuf S, Atif F, Stein DG: Progesterone and vitamin D: Improvement after traumatic brain injury in middle-aged rats. Horm Behav 64:527-538, 2013. https://doi.org/10.1016/j.yhbeh.2013.06.009

43. Verslegers M, Lemmens K, Van Hove I, Moons L: Matrix metalloproteinase-2 and -9 as promising benefactors in development, plasticity and repair of the nervous system. Prog Neurobiol 105:60-78, 2013. https://doi.org/10.1016/j.pneurobio.2013.03.004

44. Zhu G, Li J, He L, Wang X, Hong X: MPTP-induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF-TrkB pathway. Br J Pharmacol 172:2354-2368, 2015. https://doi.org/10.1111/bph.13061